IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 87.85

Change

+0.45 (+0.51)%

Market Cap

N/A

Volume

0.09M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-28 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.55 (+0.40%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

+0.24 (+0.37%)

USD 2.50B
FXH First Trust Health Care AlphaD..

+0.33 (+0.33%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

+0.03 (+0.04%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.34 (+1.67%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

+0.46 (+0.48%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.47 (+1.65%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.04 (-0.15%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.70 (+1.23%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.24 (+1.28%)

USD 0.01B

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.99 % 0.00 %

+0.79 (+0.59%)

USD 1.47B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

+0.09 (+0.59%)

CAD 0.56B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.19% 90% A- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.19% 90% A- 75% C
Trailing 12 Months  
Capital Gain -1.81% 38% F 40% F
Dividend Return 1.44% 100% F 29% F
Total Return -0.37% 57% F 34% F
Trailing 5 Years  
Capital Gain 28.83% 67% D+ 50% F
Dividend Return 8.02% 89% A- 18% F
Total Return 36.85% 67% D+ 42% F
Average Annual (5 Year Horizon)  
Capital Gain 4.29% 71% C- 52% F
Dividend Return 5.24% 71% C- 47% F
Total Return 0.95% 74% C 23% F
Risk Return Profile  
Volatility (Standard Deviation) 12.46% 76% C+ 72% C
Risk Adjusted Return 42.06% 81% B- 58% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike